Cardiology and Therapy (Apr 2023)

Clinical Decision Pathway for the Use of Fondaparinux in the Management of Acute Coronary Syndrome (ACS) in Hospitals with and Without Catheter Laboratories: An Expert Opinion from India

  • Saumitra Ray,
  • Bharat Shivdasani,
  • Jagdish Chander Mohan,
  • V. T. Shah,
  • Jagdish Hiremath,
  • Rajiv Karnik,
  • Bhupen Desai,
  • Hemant Madan,
  • Rajeev Garg,
  • Johann Christopher

DOI
https://doi.org/10.1007/s40119-023-00312-x
Journal volume & issue
Vol. 12, no. 2
pp. 261 – 274

Abstract

Read online

Abstract The current recommendations by Indian experts who are focused on the challenges in the management of patients with acute coronary syndrome (ACS) in rural areas, due to limited catheterization (CATH) lab facilities and interventional cardiologist coverage across the country, are described. 120 cardiologist experts drafted recommendations during ten advisory board meetings conducted from April to May 2022. Experts framed statements based on experience, collective clinical judgment from practical experience, and available scientific evidence regarding ACS. The consensus positioned fondaparinux as highly useful in non-CATH-lab-based hospitals for patients diagnosed with non-ST elevation acute coronary syndrome (NSTE-ACS) and ST elevation acute coronary syndrome (STE-ACS) patients who cannot be shifted to percutaneous coronary intervention (PCI)-capable centres, or for patients who are thrombolysed at peripheral centres.

Keywords